Budget impact of Relutrigine
1 evidence topic · 1 source
Summary
The available economic material is a U.S. sales forecast, ranging from $5 million in 2026 to $685 million in 2030. These figures describe projected sales, not a payer budget-impact model or annual treatment cost per participant.